Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study

Background Itolizumab downregulates the synthesis of proinflammatory cytokines and adhesion molecules by inhibiting CD6 leading to lower levels of interferon-γ, interleukin-6, and tumor necrotic factor-α and reduced T-cell infiltration at inflammatory sites. This study aims to compare the effects of...

全面介紹

書目詳細資料

發表在:	Acute and Critical Care
Main Authors:	Abhyuday Kumar, Neeraj Kumar, Arunima Pattanayak, Ajeet Kumar, Saravanan Palavesam, Pradhan Manigowdanahundi Nagaraju, Rekha Das
格式:	Article
語言:	英语
出版:	Korean Society of Critical Care Medicine 2024-05-01
主題:	covid-19 itolizumab management tocilizumab
在線閱讀:	http://www.accjournal.org/upload/pdf/acc-2023-00983.pdf